Pfizer (NYSE:PFE)'s pipeline has been the subject of much speculation (and some derision) lately as the company has been spotlighted in its attempts to juice growth by purchasing British pharma AstraZeneca. But there are exciting opportunities in Pfizer's pipeline -- for example: Bococizumab, the PCSK9 inhibitor that has lots of investors excited. Even so, there is one drug that really seems to stand out as perhaps the most exciting opportunity in Pfizer's pipeline: Breast cancer drug palbociclib, which was recently submitted for FDA approval.
And in the video below, from Where The Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson lay out the potential opportunity for palbociclib and why investors are so excited about the drug.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.